Unlocking the Potential of Nuclear Pore Complex-Interacting Protein Family Member B4 as a Drug Target or Biomarker
Unlocking the Potential of Nuclear Pore Complex-Interacting Protein Family Member B4 as a Drug Target or Biomarker
The nuclear pore complex (NPC) plays a critical role in the regulation of nuclear traffic, including the transport of proteins involved in various cellular processes. Nuclear pore complex-interacting protein family member B4 (NPIPB4) is a protein that has been identified as a potential drug target or biomarker. In this article, we will explore the biology of NPIPB4, its potential drug targets, and its potential as a biomarker for various diseases.
Overview of NPIPB4
NPIPB4 is a protein that belongs to the NPIPB family, which is known for its involvement in the regulation of nuclear pore complex. This family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NBO), which is responsible for the interaction with the nuclear pore complex.
NPIPB4 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is highly conserved, with a calculated pI of 6.3, and is capable of forming a stable complex with the nuclear pore complex.
Drug Target Potential
NPIPB4 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are relevant to various diseases. One of the key reasons for its potential as a drug target is its involvement in the regulation of the transport of proteins involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
In neurodegenerative diseases, the build-up of abnormally aggregated proteins, including beta-amyloid and tau, is thought to contribute to the progression of the disease. The regulation of protein transport through the nuclear pore complex is believed to play a role in the build-up of these abnormally aggregated proteins. Therefore, targeting the regulation of protein transport through the nuclear pore complex by NPIPB4 may be a promising strategy for the development of new treatments for neurodegenerative diseases.
Biomarker Potential
NPIPB4 has also been identified as a potential biomarker for various diseases due to its expression in various tissues and its ability to form stable complexes with the nuclear pore complex. One of the key potential applications of NPIPB4 as a biomarker is its potential to be used as a diagnostic marker for various diseases, including cancer.
The expression of NPIPB4 has been observed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, the stability of NPIPB4-nucleotide-binding oligomerization domain interactions suggests that it could be used as a diagnostic marker for cancer progression.
Conclusion
NPIPB4 is a protein that has been identified as a potential drug target and biomarker due to its involvement in the regulation of the nuclear pore complex and its expression in various tissues. Its potential as a drug target is based on its involvement in the regulation of cellular processes that are relevant to various diseases, including neurodegenerative diseases. As a biomarker, NPIPB4 is potentially useful for the diagnosis of cancer and other diseases. Further research is needed to fully understand the role of NPIPB4 as a drug target and biomarker, and to explore its potential clinical applications.
Protein Name: Nuclear Pore Complex Interacting Protein Family Member B4
The "NPIPB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPIPB4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NPIPB5 | NPIPB7 | NPIPB8 | NPIPB9 | NPIPP1 | NPL | NPLOC4 | NPM1 | NPM1P13 | NPM1P21 | NPM1P22 | NPM1P25 | NPM1P27 | NPM1P28 | NPM1P35 | NPM1P42 | NPM1P47 | NPM1P48 | NPM2 | NPM3 | NPNT | NPPA | NPPA-AS1 | NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT
